GlassScriptPhysician profile
Aarti Desai
NPI 1922263177
$2,050.78
in general payments reported to CMS, 2019-2025
25 companies · $706 in 2025
The $706 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $736 · 2020: $294 · 2021: $130 · 2022: $135 · 2023: $15.38 · 2024: $34.70 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $755.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| One Lambda, INC. | $205.09 | 2025 | |
| Gilead Sciences, INC. | $198.84 | 2019-2025 | |
| Insmed, INC. | $198.50 | 2019-2021 | |
| Cvrx, INC. | $186.25 | 2025 | Barostim Neo System |
| Abbvie INC. | $146.67 | 2021-2025 | |
| Viiv Healthcare Company | $144.74 | 2019-2025 | Dovato, Cabenuva |
| Mylan Specialty L.P. | $124.93 | 2020 | |
| Paragonix Technologies, INC. | $120.88 | 2025 | Sherpapak |
| Astellas Pharma US INC | $104.25 | 2019 | |
| Philips North America LLC | $101.90 | 2019 | |
| Merck Sharp & Dohme LLC | $93.60 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $64.25 | 2019-2020 | |
| Napo Pharmaceuticals INC | $56.96 | 2019-2020 | |
| Melinta Therapeutics, LLC | $56.84 | 2019-2020 | |
| Biomerieux INC | $34.70 | 2024 | Biofire Spotfire Respiratory (R) Panel, Filmarray Bcid Panel |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $34.07 | 2025 | Fetroja |
| Allergan, INC. | $32.71 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $24.86 | 2019-2020 | |
| Pfizer INC. | $23.33 | 2022 | |
| Paratek Pharmaceuticals, INC. | $21.88 | 2022 | |
| Janssen Pharmaceuticals, INC | $18.20 | 2022 | |
| Vyera Pharmaceuticals, LLC | $17.32 | 2019 | |
| Glaxosmithkline, LLC. | $15.38 | 2023 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.33 | 2021 | |
| Advanced Respiratory, INC | $12.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aarti Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.